CALD

• AffyImmune Therapeutics, Inc ., a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, announced today the appointment of Matt Britz to Chief Executive Officer and Pete Gelinas as Senior Vice President of Chemistry, Manufacturing, and Controls.
• Matt is well-suited to lead AffyImmune as CEO as the Company accelerates clinical development of AIC100 in thyroid cancer, and in other indications with high unmet medical need.
• Matt Britz joined AffyImmune in June 2021 as Senior Vice President (SVP), Business Development and was promoted to Chief Operating Officer in January 2022.
• Pete Gelinas brings over 15 years of extensive experience in Manufacturing and CMC Product Development to AffyImmune.

• The film can be found on Neuraxpharm's and Minoryx's websites, YouTube and LinkedIn channels.
• Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, said: "The impact this disease has on patients and their families cannot be overstated.
• We hope that this film will raise awareness and understanding of the condition."
• Minoryx and Neuraxpharm strongly believe that leriglitazone has a positive benefit / risk balance in patients with cALD.

• You feel light-headed and you’re pretty sure you’re having a heart attack.
• It’s well known getting the right medical help early when you’re having a heart attack can be a life or death decision.
• Why do so many migrants wait so long to seek help or go to hospital after chest pains?

What we know so far

• We found a median pre-hospital delay time of six hours for Sub-Saharan African migrants.
• Importantly, decision time to seek help takes up to 83% of pre-hospital delay in migrant patients, compared to only 48% for Australian-born patients.


By contrast, the median decision time for Australians was 1.5 hours.

Why might some migrants delay seeking help for chest pains?

Our subsequent research has shown certain factors may influence how long a migrant waits to seek help after chest pains first appear. These include things such as:
• Non-English speaking migrants are more likely to wait hours before seeking help, while migrants from English-speaking backgrounds sought medical care more quickly.
• And once migrants do decide to seek medical help for chest pain, they often did not call an ambulance straight away.
• Migrants working in Australia on skilled visas, by contrast, may delay seeking help because they have no health insurance, are worried about their jobs or fear hefty ambulance fees or medical costs.
• They often relied financially on younger family members and wanted to avoid being a “burden” to them by seeking help for their chest pain.

What can be done?

Our long-running research, which involved consultation and collaboration with stakeholders and migrant communities in Australia, has revealed some startling inequities. Some key interventions, however, would make a big difference. These include:
• These long waiting periods widen the gap and worsen the health inequities in our society.
• Hannah Wechkunanukul is on a committee of the Public Health Association of Australia (SA Brach), Australian Health Promotion Association (SA Brach).

• bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the first quarter ended March 31, 2023, including recent commercial and operational progress, and regulatory updates.
• In the weeks since the Company’s last commercial update, bluebird continues to build on the launch of ZYNTEGLO for beta-thalassemia.
• The first commercial ZYNTEGLO infusion has been completed and the Company anticipates recognizing revenue in Q2 2023.
• Please see our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 for further information regarding our cash runway guidance and other financial results.